Holly Pederson Discusses the Unique Contributions of Nurses

Article

Holly Pederson, MD, discusses the unique contributions of nurses on her team.

Holly Pederson, MD, director of Medical Breast Services, Cleveland Clinic, discusses the unique contributions of nurses on her team.

Nurses bring a wealth of experience in dealing with patients and caring for the whole person. Subspecialists, according to Pederson, may not have the time to provide care for everything a patient may need.

Nurses are also available to patients at the times they need it most and can provide advice on menopausal symptoms, bone density issues, family issues, anxiety and more.

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue diagram of a human's bones and tissue, with the breast tissue and tumor in focus

Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA

Chris Ryan
February 7th 2025
Article

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

Simple line illustration on a yellow background of a breast with the tissue illustrated

T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval

Chris Ryan
February 5th 2025
Article

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.